Publisher Correction: Allogeneic CD5-specific CAR-T therapy for relapsed\/refractory T-ALL: a phase 1 trial

.Nature Medicine, Released online: 16 Oct 2024 doi:10.1038/ s41591-024-03348-1Publisher Modification: Allogeneic CD5-specific CAR-T treatment for relapsed/refractory T-ALL: a period 1 trial.